Trials / Completed
CompletedNCT02412644
Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
Efficacy and Safety of Combining Apremilast 30mg Bid With Narrowband UVB in the Treatment of Moderate-to-severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Psoriasis Treatment Center of Central New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy
Detailed description
Primary Objective: To evaluate the effectiveness of Otezla (apremilast®) in promoting maintenance of response in those subjects who obtained PASI-75 at week 12 of phototherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | apremilast |
Timeline
- Start date
- 2015-05-28
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2015-04-09
- Last updated
- 2019-01-28
- Results posted
- 2019-01-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02412644. Inclusion in this directory is not an endorsement.